Blog · AUG 5, 2026 · 3 min read

Why We Still Say No to Building a Fourth Product

We keep getting reasonable pitches for a fourth product, and we keep saying no.

By Team Medismo•Company

Since PatientVoice launched, we have been asked more than once what is next. A patient-side app. A billing product for hospitals. An analytics dashboard sold separately from Connex. Each pitch arrives with a reasonable-sounding argument, and we have said no to all of them.

The pattern behind every good idea

Every one of these suggestions follows the same shape: we already have the data, we already have the relationship, so why not extend it. That argument is seductive because it is not wrong. We probably could build a reasonable version of most of these things.

But being able to was never our bar. Our bar has always been whether this is the narrowest possible fix for a problem multiple customers are independently describing to us, unprompted. FieldVoice cleared that bar for pharma reps. Connex cleared it for doctor-pharma scheduling. PatientVoice cleared it for the specific gap between hospital discharge and follow-up.

None of the fourth-product pitches have cleared it yet. They are extensions of convenience, not answers to a problem hospitals or pharma teams are actively raising with us in the same way PatientVoice was raised with us five separate times in six weeks before we built it.

What discipline actually costs

Saying no here is not free. It means walking away from revenue we could plausibly capture, and it means some competitors will build the broader platform and win customers who want one vendor for everything. We accept that trade.

Three focused products, each excellent at one job, is a harder sell in a single meeting than one platform with a feature for everything. It is also the reason FieldVoice, Connex, and PatientVoice can each move fast without breaking the other two. A fourth product built for convenience rather than necessity would slow all three down, not speed anything up.

So the answer, for now, stays no. Not because we lack ideas, but because none of them have earned their way onto the list the way the first three did, and we are not going to lower the bar just because we finally have the team size to build more.

product-strategyfocusfounder-notes